Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metadherin siRNA
- Development stage
- Preclinical
- Lead developer
- Ontario Cancer Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
Metadherin siRNA is a small interfering RNA (siRNA) designed to silence the expression of metadherin (MTDH), also known as astrocyte elevated gene-1 (AEG-1). MTDH is an oncogene that is frequently overexpressed in various malignancies, including head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), where it promotes tumor progression, epithelial-mesenchymal transition (EMT), and metastasis. The siRNA works through the RNA interference pathway to degrade MTDH mRNA, thereby reducing protein levels and inhibiting downstream signaling cascades such as the PI3K/Akt pathway. Preclinical studies have demonstrated that knockdown of MTDH using siRNA significantly reduces cancer cell viability, migration, invasion, and in vivo tumor growth, suggesting that targeting this pathway could be a novel therapeutic strategy for improving outcomes in patients with head and neck cancers.
- Other names
- MTDH siRNAAEG-1 siRNAAEG1 siRNAAEG 1 siRNAastrocyte elevated gene-1 siRNA
02
Targets
MTDH (Metadherin)
Beyond the preview
Go deeper on metadherin siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metadherin siRNA.